CASI Pharmaceuticals, Inc. (NASDAQ:CASI) posted its earnings results on Tuesday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01, Bloomberg Earnings reports.

Shares of CASI Pharmaceuticals (NASDAQ:CASI) opened at $2.63 on Thursday. CASI Pharmaceuticals has a 12-month low of $0.91 and a 12-month high of $4.84.

Several equities research analysts have issued reports on CASI shares. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. Maxim Group restated a “buy” rating and set a $4.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. Finally, ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 15th.

COPYRIGHT VIOLATION WARNING: “CASI Pharmaceuticals, Inc. (CASI) Posts Quarterly Earnings Results” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at

In other CASI Pharmaceuticals news, Director Wei-Wu He acquired 100,000 shares of the stock in a transaction that occurred on Tuesday, October 10th. The shares were bought at an average price of $1.95 per share, for a total transaction of $195,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders purchased 996,329 shares of company stock worth $1,647,138 in the last quarter. 13.01% of the stock is currently owned by company insiders.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Stock Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.